William E. Fantegrossi

Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity

Lisa K. Brents, Emily E. Reichard, Sarah M. Zimmerman et al. · PLoS ONE · 2011 · 210 citations · Full text

Quantitative Measurement of JWH-018 and JWH-073 Metabolites Excreted in Human Urine

Cindy L. Moran, Vi-Huyen Le, Krishna C. Chimalakonda et al. · Analytical Chemistry · 2011 · 148 citations

In vivo Effects of Abused ‘Bath Salt’ Constituent 3,4-methylenedioxypyrovalerone (MDPV) in Mice: Drug Discrimination, Thermoregulation, and Locomotor Activity

William E. Fantegrossi, Brenda M. Gannon, Sarah M. Zimmerman et al. · Neuropsychopharmacology · 2012 · 147 citations · Full text

Biochemistry, Medicine, Behavioural Pharmacology +9

Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats

William E. Fantegrossi, Andrew W. Harrington, Christina Lynn Kiessel et al. · Pharmacology Biochemistry and Behavior · 2006 · 144 citations

Molecular Pharmacology, Medicinal Chemistry, Hallucinogen-like Actions +7

Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity

Lisa K. Brents, Anna Gallus‐Zawada, Anna Radomińska‐Pandya et al. · Biochemical Pharmacology · 2012 · 142 citations · Full text

Cannabis Use, Partial Agonist Activity, Biochemistry +11